Prognostic Model Based on Systemic Inflammatory Response and Clinicopathological Factors to Predict Outcome of Patients with Node-Negative Gastric Cancer

Jinglei Qu(First Hospital of China Medical University), Yunpeng Liu(Shenyang Institute of Automation), Ping Yu(First Hospital of China Medical University), Jing Shi(Singapore Institute of Technology), Mingfang Zhao(First Hospital of China Medical University), Lingyu Fu(Heilongjiang University), Jing Liu(China Pharmaceutical University), Jingdong Zhang(Liaoning Cancer Hospital & Institute), Bo Jin, Zhi Li(Central Hospital Affiliated to Shenyang Medical College), Xiujuan Qu(First Hospital of China Medical University)
PLoS ONE
June 15, 2015
10.1371/journal.pone.0128540
Cited by 23

Related Papers

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417